Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting October 19

Nymox Pharmaceutical Corporation NYMX today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Central Section of the American Urological Association Meeting in Rancho Mirage, CA October 19, 2011. The paper is authored by leading independent clinical research investigators participating in the U.S. clinical trials of NX-1207.